AQST
AQST
Positions held
Your positionsAQST isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
2026-09-17 · Aquestive Therapeutics Resubmits Anaphylm NDA to FDA
2026-09-08 · Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
2026-09-01 · Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
2026-08-18 · Aquestive (AQST) Q2 2026 Earnings Call Transcript
2026-08-12 · Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ...
2026-08-12 · Aquestive Therapeutics Q2 Earnings Call Highlights
2026-08-12 · Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-11 · Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 · Aquestive Therapeutics Q2 Loss Widens, Revenue Rises
2026-08-11 · Aquestive Therapeutics: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patterns